Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
作者机构:Department of Biochemistry and Molecular BiologyUniversity of New MexicoAlbuquerqueNM 87131USA
出 版 物:《Acta Pharmaceutica Sinica B》 (药学学报(英文版))
年 卷 期:2024年第14卷第9期
页 面:3785-3801页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金:the NIGMS funded Academic Science Education and Research Training(ASERT,K12-GM088021)Program at the University of New Mexico Health Sciences Center Xiang Xue received partial funding support from the National Institutes of Health(P20 GM130422) a Research Scholar Grant from the American Cancer Society(RSG-18-050-01-NEC) Environmental Health and Toxicology Pilot Awards from UNM Center for Native Environmental Health Equity Research(P50 MD015706) New Mexico Integrative Science Program Incorporating Research in Environmental Sciences(NM-INSPIRES,1P30ES032755) Xiang Xue also acknowledges funding support from a Research Program Support Pilot Project Award from UNM comprehensive cancer center(P30CA118100) the Cardiovascular and Metabolic Disease Research Program Pilot Project Grant from UNMHSC Office of Research Signature Programs
主 题:Ferroptosis Colorectal cancer Inflammatory bowel disease Cell death Molecular mechanisms Iron metabolism Drug therapies Targeted therapeutics
摘 要:Ferroptosis is a novel type of regulated cell death(RCD)involving iron accumulation and lipid *** its discovery in 2012,various studies have shown that ferroptosis is associated with the pathogenesis of various *** cell death has also been linked to intestinal dysfunction but can act as either a positive or negative regulator of intestinal disease,depending on the cell type and disease *** continued investigation of mechanisms underlying ferroptosis provides a wealth of potential for developing novel *** the growing prevalence of intestinal diseases,particularly colorectal cancer(CRC)and inflammatory bowel disease(IBD),this review article focuses on potential therapeutics targeting the ferroptotic pathway in relation to CRC and IBD.